中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

250 records (took 0.045 seconds)

    Systems and Methods for Reducing CPU Time to Compute State Space of Resource Allocation System
    145.
    发明申请
    Systems and Methods for Reducing CPU Time to Compute State Space of Resource Allocation System 审中-公开

    公开(公告)号：US20190018708A1

    公开(公告)日：2019-01-17

    申请号：US15649634

    申请日：2017-07-13

    Applicant: Macau University of Science and Technology

    Inventor： Zhiwu LI ,  Oussama KAROUI ,  Naiqi WU ,  Mohamed KHALGUI

    IPC: G06F9/50 ,  G06F9/48

    CPC classification number: G06F9/5038 ,  G06F9/4887

    Abstract: Given a sequential resource allocation system (RAS) topology structure, a state space, called an impulse state space, corresponding to the impulse response of a linear time-invariant system (LTS), is computed by small enough configuration of the considered RAS. Given an initial resource configuration of a RAS which corresponds to an input of an LTS, a complete state enumeration can be obtained by defining the convolution of this configuration with the pre-computed impulse state space. One example embodiment reduces central processing unit (CPU) time to process instructions that compute a target state space of a RAS includes constructing an initial RAS and an initial state space, and extending the initial state space iteratively under a target resource configuration.

    BUFADIENOLIDE FOR TREATMENT OF NON-SMALL CELL LUNG CANCER
    146.
    发明申请
    BUFADIENOLIDE FOR TREATMENT OF NON-SMALL CELL LUNG CANCER 审中-公开

    公开(公告)号：US20180348222A1

    公开(公告)日：2018-12-06

    申请号：US15610709

    申请日：2017-06-01

    Applicant: Macau University of Science and Technology

    Inventor： Liang Liu ,  Lai-Han Elaine Leung ,  Xiao-Jun Yao ,  Run-Ze Li ,  Xing-Xing Fan

    IPC: G01N33/574 ,  A61K31/56 ,  A61K31/585

    Abstract: A method of treating a subject, in particular a human, suffering from non-small cell lung cancer includes administering a bufadienolide to the subject. A method of inhibiting the proliferation and inducing the cell death of non-small cell lung cancer cells, a method of inhibiting the Epidermal growth factor receptor (EGFR) kinase activity in non-small cell lung cancer cells harboring an abnormality in the EGFR gene, and a method of inhibiting Na+/K+-ATPase in non-small cell lung cancer cells includes contacting those cells with a bufadienolide. Proscillaridin A as bufadienolide, with the structure of Formula (III) has advantageously high cytotoxicity against EGFR-dependent non-small cell lung cancer at nano-molar levels while having low toxicity to normal lung cells.

    Cluster tool apparatus and a method of controlling a cluster tool apparatus
    148.
    发明授权
    Cluster tool apparatus and a method of controlling a cluster tool apparatus 有权

    公开(公告)号：US10134613B2

    公开(公告)日：2018-11-20

    申请号：US15272706

    申请日：2016-09-22

    Applicant: Macau University of Science and Technology

    Inventor： Yan Qiao ,  Mengchu Zhou ,  Naiqi Wu ,  Zhiwu Li ,  Qinghua Zhu

    IPC: H01L21/677 ,  H01L21/67

    Abstract: A system and method for a cluster tool apparatus for processing a semiconductor product including processing modules located adjacent each other and configured to process a semiconductor module, loadlocks configured to retain and dispense unprocessed semiconductor products and each positioned adjacent one of the processing modules, a robot configured to load, transfer and unload a semiconductor product to and from the processing modules, a hardware controller in communication with the robot and executing a method to close down the cluster tool apparatus to an idle state, the method including determining a status of the processing modules, determining if a close down process is required based on the status or based on a close down signal, and, if required, determining a schedule for a close down process based on a semiconductor product residency parameter, and controlling the operation of the robot based on the schedule to perform the close down process.

    SYSTEM AND METHOD FOR CONTROLLING A CONVERTER CIRCUIT
    149.
    发明申请
    SYSTEM AND METHOD FOR CONTROLLING A CONVERTER CIRCUIT 审中-公开

    公开(公告)号：US20180323616A1

    公开(公告)日：2018-11-08

    申请号：US15587543

    申请日：2017-05-05

    Applicant: Macau University of Science and Technology

    Inventor： Chuan Sun ,  Xiao Dong Li

    IPC: H02J3/38 ,  H02M3/335 ,  H02M7/04 ,  H02M7/44

    CPC classification number: H02J3/383 ,  H02J3/386 ,  H02M3/33546 ,  H02M7/04 ,  H02M7/44

    Abstract: Controlling operation of a converter circuit regulating power transfer between first and second voltage sources includes comparing a detected power value in the converter circuit with a power command value; determining a converter gain based on detected first and second voltage levels of the first and second voltage sources; and determining operation signals for transmitting to switches in the converter circuit during a steady state to control switching time and duration. When the detected power value differs from the power command value, the method includes determining values of two or more variables associated with adjustment of switching time and duration based on the detected first and second voltage levels; and determining operation signals to transmit to the switches during a power transition state based on the determined values of the two or more variables to adjust switching time and switching duration of the switches, thereby regulating power transition.

    ALK Kinase Inhibitor and its use
    150.
    发明授权
    ALK Kinase Inhibitor and its use 有权

    公开(公告)号：US10111876B2

    公开(公告)日：2018-10-30

    申请号：US15239288

    申请日：2016-08-17

    Applicant: Macau University of Science and Technology

    Inventor： Xiao-Jun Yao ,  Elaine Lai-Han Leung ,  Lian-Xiang Luo ,  Liang Liu

    IPC: A61K31/519

    Abstract: A compound for treating a disease, in particular cancer like non-small cell lung cancer, exceptionally inhibits activity of oncogenic ALK kinase. Compositions, particularly pharmaceutical compositions, are provided comprising this compound. Methods for targeting cancer cells harboring an abnormality in the ALK gene are also The compound for treating a disease has certain structural elements, namely a tricyclic, more specifically heterocyclic, backbone as the core part of the compound at least one highly electronegative atom in form of a tertiary amine attached to the backbone via an at most 6-membered linking group with a terminal highly electronegative atom in form of a nitrogen as secondary amine, and a further hydrophobic moiety fused to the backbone. The structural components allow for an advantageous interaction with the ALK kinase domain. The compound therefor represents a highly promising treatment option for patients in particular those bearing ALK-dependent non-small cell lung cancer.

Patent Agency Ranking